CV Sciences (CVSI) EBITDA Margin Growth (3y) (2016 - 2026)
CV Sciences (CVSI) EBITDA Margin Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 1,129.00 |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 2.00 |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 59.00 |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | -1,031.00 |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -925.00 |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | -46.00 |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 6,666.00 |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | 1,705.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,705.00 |
| Mar 31, 2026 | -14,886.00 |
| Dec 31, 2025 | 5,266.00 |
| Sep 30, 2025 | 1,533.00 |
| Jun 30, 2025 | 5,233.00 |
| Mar 31, 2025 | 3,437.00 |
| Dec 31, 2024 | 16,133.00 |
| Sep 30, 2024 | 4,953.00 |
| Jun 30, 2024 | 5,370.00 |
| Mar 31, 2024 | 4,877.00 |
| Dec 31, 2023 | 15,865.00 |
| Sep 30, 2023 | 4,594.00 |
| Jun 30, 2023 | 5,917.00 |
| Mar 31, 2023 | 20,324.00 |
| Dec 31, 2022 | 2,380.00 |
| Sep 30, 2022 | -971.00 |
| Jun 30, 2022 | -6,339.00 |
| Mar 31, 2022 | 2,883.00 |
| Dec 31, 2021 | -19,735.00 |
| Sep 30, 2021 | -8,428.00 |